In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


This content is currently on FREE ACCESS, enjoy another 76 days of free consultation

 

Inhibition of platelet aggregation after subcutaneous administration of a single-dose of selatogrel, a novel P2Y12 antagonist, in acute myocardial infarction: a randomised open-label phase 2 study

Session Emerging treatments in acute coronary syndromes

Speaker Peter R Sinnaeve

Congress : ESC Congress 2019

  • Topic : coronary artery disease, acute coronary syndromes, acute cardiac care
  • Sub-topic : Acute Coronary Syndromes: Pharmacotherapy
  • Session type : Advances in Science
  • FP Number : 5232

Authors : PR Sinnaeve (Leuven,BE), G Fahrni (Basel,CH), D Schelfaut (Aalst,BE), AS Spirito (Bern,CH), CH Mueller (Basel,CH), J-M Frenoux (Allschwil,CH), A Hmissi (Allschwil,CH), C Bernaud (Allschwil,CH), T Moccetti (Lugano,CH), SA Atar (Safed,IL), MV Valgimigli (Bern,CH)

Authors:
PR Sinnaeve1 , G Fahrni2 , D Schelfaut3 , AS Spirito4 , CH Mueller5 , J-M Frenoux6 , A Hmissi7 , C Bernaud6 , T Moccetti8 , SA Atar9 , MV Valgimigli10 , 1University Hospitals (UZ) Leuven, Campus Gasthuisberg, Department of Cardiology - Leuven - Belgium , 2University Hospital Basel, Department of Cardiology - Basel - Switzerland , 3Cardiovascular Center Aalst - Aalst - Belgium , 4Bern University Hospital, Department of Cardiology - Bern - Switzerland , 5University Hospital Basel, Department of Cardiology and Cardiovascular Research Institute Basel (CRIB) - Basel - Switzerland , 6Idorsia Pharmaceuticals Ltd, Therapeutic Area Units - Allschwil - Switzerland , 7Idorsia Pharmaceuticals Ltd, Biometry - Allschwil - Switzerland , 8Cardiocentro Ticino - Lugano - Switzerland , 9Azrieli Faculty of Medicine, Department of Cardiology - Safed - Israel , 10Inselspital, University of Bern - Bern - Switzerland ,

Citation:

Background: Oral P2Y12 receptor antagonists exhibit a delayed onset of platelet inhibition in patients experiencing acute myocardial infarction (AMI). Selatogrel is a potent, reversible, and highly selective P2Y12 receptor antagonist with a rapid onset and offset of action when administered subcutaneously.
Purpose: To assess inhibition of platelet aggregation (IPA) after subcutaneous (s.c.) single-dose administration of selatogrel in patients with AMI receiving standard concomitant therapy.
Methods: Male and postmenopausal female adults (=85 years) presenting with type 1 AMI (ST-elevation MI [STEMI] or non-STEMI [NSTEMI]) and onset of AMI symptoms >30 min to <6 h were randomised (1:1) to receive a single s.c. dose of either 8 mg or 16 mg selatogrel. Blood samples were collected at baseline and at 15, 30, and 60 min post-dose and evaluated for ADP-induced platelet aggregation (expressed as P2Y12 reaction units [PRU]) using VerifyNow. The primary endpoint was the response to treatment (defined by PRU <100) at 30 min post-dose. Safety was assessed up to 48 h post-dose.
Results: Forty-seven patients (median age 69 y; 72% male; 62% STEMI; 94% Killip class 1) received 8 mg (N=24) or 16 mg (N=23) selatogrel. Study-treatment concomitant medications included acetylsalicylic acid (98%), P2Y12 inhibitors (96%), heparins (94%), statins (94%), nitrates (68%) and morphine (38%). Oral ticagrelor (92%) with corresponding loading doses was only administered after selatogrel. The proportion of patients meeting the primary endpoint (responders) 30 min post-dose was 91% (95% CI: 72, 99) and 95% (95% CI: 77, 100) with 8 and 16 mg, respectively (p<0.001 for both doses). Response rates were independent from STEMI/NSTEMI diagnosis, age and sex. A response was observed as early as 15 min (8 mg: 75% of patients [95% CI: 53, 90]; 16 mg: 91% of patients [95% CI: 72, 99]), and sustained up to 60 min post-dose (8 mg: 75% of patients [95% CI: 53, 90]; 16 mg: 96% of patients [95% CI: 78, 100]). Platelet reactivity was decreased following selatogrel administration (Figure; interquartile range [box], min and max [whiskers], median and mean [horizontal line and symbol, respectively, within the box]). Overall, 43% of patients had =1 treatment-emergent adverse event (TEAE), which were mainly of mild/moderate intensity. Ventricular tachycardia ([VT] 8 mg: 5/24; 16 mg: 3/23) was the most frequent TEAE. Treatment-emergent serious AEs of VT were reported in two patients receiving 8 mg (one patient also experienced ventricular fibrillation) and one patient receiving 16 mg selatogrel. Post-procedural haemorrhage (mild) occurred in one patient: bleeding at radial access after percutaneous coronary intervention (~1 h after selatogrel 8 mg).
Conclusion: Single-dose administration of s.c. selatogrel (8 mg and 16 mg) induced a rapid IPA response in patients with AMI at 30 min (as early as 15 min and maintained at 60 min post-dose) and was well-tolerated with no major bleeding events.

This content is currently on FREE ACCESS, enjoy another 76 days of free consultation

 



Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from ESC Congress and ESC Asia with APSC & AFC
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s congress resources
  • 3Under 40 or in training - with a Combined Membership, access resources from all congresses
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are